Filana Therapeutics
FLNA
117 hedge funds and large institutions have $25.6M invested in Filana Therapeutics in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 43 reducing their positions, and 36 closing their positions.
71% more call options, than puts
Call options by funds: $3.28M | Put options by funds: $1.93M
3.46% less ownership
Funds ownership: 36.19% → 32.73% (-3.5%)
15% less funds holding
Funds holding: 137 → 117 (-20)
35% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 43
38% less capital invested
Capital invested by funds: $41.1M → $25.6M (-$15.5M)
53% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
+$1.14M |
| 2 |
JP Morgan Chase
New York
|
+$981K |
| 3 |
Two Sigma Advisers
New York
|
+$762K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$685K |
| 5 |
Goldman Sachs
New York
|
+$549K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$985K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$971K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$915K |
| 4 |
BlackRock
New York
|
-$669K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$659K |
FLNA Hedge Fund Activity: Q1 2025 in Review
117 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2025, worth a combined $25.6M — down 38% from $41.1M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of FLNA and 17 opened new positions — a net loss of 19 holders — while 43 trimmed existing stakes and 28 added.
The largest buyer was GMT Capital, opening a new position worth an estimated $1.14M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $985K sold.
- 117 institutional investors held Filana Therapeutics (FLNA) as of Q1 2025, down from 137 in Q4 2024.
- Funds reported $25.6M of Filana Therapeutics stock for Q1 2025, down 38% quarter-over-quarter.
- 17 funds opened new Filana Therapeutics positions in Q1 2025 and 36 closed out, a net change of -19 holders.
- The largest Filana Therapeutics buyer in Q1 2025 was GMT Capital, an estimated $1.14M added.
- The largest Filana Therapeutics seller in Q1 2025 was Rosalind Advisors, an estimated $985K sold.
Based on aggregated 13F filings for Q1 2025.